Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…Abstract Number: 2476 • ACR Convergence 2025
Blinatumomab in rapid progressive systemic sclerosis
Background/Purpose: Systemic sclerosis is a severe, potentially fatal disease, characterized by progressive fibrosis of skin and internal organs. Blinatumomab is a bispecific CD3/CD19-T-cell engager (BiTe)…Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…Abstract Number: 0656 • ACR Convergence 2025
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Background/Purpose: B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanized monoclonal antibody belimumab with 10mg/kg was effective for active patients. The efficacy of…Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…Abstract Number: 1683 • ACR Convergence 2025
Serum APRIL Is Associated With B-Cell Activation Markers, Disease Activity, and Lymphoma Risk in Sjögren Disease (SD): Data From the prospective ASSESS Cohort
Background/Purpose: Sjögren disease (SD) is a B cell driven systemic auto-immune disease, with a need for biomarkers to better assess disease activity, risk of lymphoma…Abstract Number: 0994 • ACR Convergence 2025
UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Background/Purpose: Current therapies inadequately restore immune homeostasis due to incomplete pathogenic cell clearance and limited multi-lineage targeting. UTAA91 integrates: 1) PD-1 agonist-targeted cytotoxicity: The PD-1…Abstract Number: 0646 • ACR Convergence 2025
A-319, a CD3×CD19 T Cell Engager, for the Treatment of Refractory Systemic Lupus Erythematosus: Preliminary Evidence of Autoimmune Reset
Background/Purpose: Immune reset of autoimmune disease has been proposed to be a potential benefit of T cell engagers (TCEs) and CD19 CAR T therapy. A-319,…Abstract Number: 0012 • ACR Convergence 2025
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 or B-cell maturation antigen (BCMA) have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic…Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…Abstract Number: 1666 • ACR Convergence 2025
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
Background/Purpose: IgG4-RD is a progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is a reversible, orally available inhibitor of Bruton's tyrosine kinase (BTKi). Here,…Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 17
- Next Page »